Farmas USA

Aprovechamos el rebote y me salgo de FOLD a 2,28. Que experiencia más mala. Al final se saldó con ligeras pérdodas, por lo que intentaremos seguir aprendiendo e intentarlo de nuevo en el futuro. Saludos

onvo

por linea tendencia rsi debería rebotar, pero eso es lo mismo que tener un tío en grana...

Y la vi a 10 casi 11$ no hace tanto. 100% especulativo, dónde tendrá el suelo?

Qué opinamos aquí de ONVO a medio plazo?

Acabo de ver pico compra vela minuto 172k shares de volumen en AMRN a 1,65.

 

 

ACTC

En todas partes en los últimos dos días

Mencionada ampliamente en artículo en la revista especializada GEN

http://www.genengnews.com/insight-and-intelligence/stem-cell-breakthroughs-renew-old-cloning-fears/77900111/

En el NewScience:

http://www.newscientist.com/article/dn25474-insulinmaking-cells-created-by-dollycloning-method.html#.U1-8hlfw13V

En Fidelity
https://eresearch.fidelity.com/eresearch/goto/evaluate/news/basicNewsStory.jhtml?symbols=ACTC&storyid=201404281110RTRSNEWSCOMBINED_L2N0NH18R_1&provider=RTRSNEWS&product=COMBINED&hlinks=vnhl

New Worcester Business Journal:

http://www.wbjournal.com/article/20140428/PRINTEDITION/304259985/1002

En US China Press

http://news.uschinapress.com/2014/0428/975845.shtml

En SCNT:
NEW YORK, April 28 (Reuters) - And now there are three: in the wake of announcements from laboratories in Oregon and California that they had created human embryos by cloning cells of living people, a lab in New York announced on Monday that it had done that and more.

In addition to cloning the cells of a woman with diabetes, producing embryos and stem cells that are her perfect genetic matches, scientists got the stem cells to differentiate into cells able to secrete insulin.

That raised hopes for realizing a long-held dream of stem cell research, namely, creating patient-specific replacement cells for people with diabetes, Parkinson's disease, heart failure and other devastating conditions. But it also suggested that what the Catholic Church and other right-to-life advocates have long warned of - scientists creating human embryos to order - could be imminent.

The trio of successes "increases the likelihood that human embryos will be produced to generate therapy for a specific individual," said bioethicist Insoo Hyun of Case Western Reserve University School of Medicine in Cleveland. And "the creation of more human embryos for scientific experiments is certain."

The accelerating progress in embryonic stem cell research began last May. Scientists, led by Shoukhrat Mitalipov of Oregon Health & Science University, reported they had created healthy, early-stage human embryos - hollow balls of about 150 cells - by fusing ova with cells from a fetus, in one experiment, and an infant in another.

Earlier this month, scientists at the CHA Stem Cell Institute in Seoul, South Korea, announced they had managed the same feat with skin cells from two adult men.

In each case, scientists used a version of the technique that created the sheep Dolly in 1996, the first clone of an adult mammal. Called somatic cell nuclear transfer (SCNT), the recipe calls for removing the nuclear DNA from an ovum, fusing it with a cell from a living person, and stimulating each ovum to begin dividing and multiplying. The resulting embryo includes stem cells that can differentiate into any human cell type.

While that sounds simple enough, immense technical hurdles kept scientists from achieving human SCNT over more than a decade of attempts. Now that they have a reliable recipe, including the right nutrients to sustain the eggs and the right timing to start it dividing, they have "a reproducible, reliable way to create patient-specific stem cells" via cloning, said Dr. Robert Lanza, chief scientific officer of Advanced Cell Technology(ACTC) and co-author of the CHA paper.

INCURABLE DISEASE

In the latest study, published online in Nature, scientists led by Dieter Egli of the privately-funded New York Stem Cell Foundation Research Institute derived insulin-making "beta cells" from the embryos they cloned from a 32-year-old with type-1 diabetes, an autoimmune disease in which the immune system attacks beta cells. Beta cells do not function in that incurable form of diabetes, often known as juvenile diabetes, which is treated with insulin.

The beta cells produce as much insulin as those in a healthy human pancreas, Egli said. When transplanted into lab mice, the cells functioned normally, making insulin in response to glucose.

Egli has no plans to transplant stem-cell-derived beta cells into patients with type 1-diabetes, in large part because the new cells will meet the same fate as the patient's native beta cells.

For one thing, in type-1 diabetes the immune system chews up beta cells, so the same fate could await cells transplanted into a diabetic, Egli said.

One of the most important uses of the newly created beta cells will therefore be for research, not therapy, said biologist Douglas Melton of the Harvard Stem Cell Institute, who was not involved in the study.

A key research imperative, experts said, is animal experiments to compare the therapeutic potential of cloned embryonic stem cells with stem cells made by "reprogramming" adult cells. This technique does not create or require human embryos, and so was hailed as a way to have stem-cell research without the ethical baggage.

It turns out that some cells produced this way self-destruct or die young, however, suggesting that the embryonic kind will be necessary after all.

That has resurrected a debate that flared in 2001, when U.S. President George W. Bush declared that federal funds could not be used to create human embryos for research. Existing stem cell lines, or IVF embryos, were therefore used.

But with the creation of patient-specific stem cells now scientific reality, there will likely be greater scientific interest in creating human embryos for research, returning the moral debate to the front burner.

"They are cloning human embryos and killing them for their cells," biologist David Prentice of the pro-life Family Research Council said. "There should be much more outrage." (Reporting by Sharon Begley; Editing by Julie Steenhuysen and Nick Zieminski

En BioNews:

Human cloning first: stem cells created from adult skin cells

28 April 2014

By Sarah Guy
Appeared in BioNews 751

Scientists have used a cloning technique to successfully create human embryonic stem cells from adult cells for the first time.

The technique has worked previously using cells from babies, but it was thought that the natural mutations that occur as they age would mean that it could not be achieved using adult cells. But the researchers had success using skin cells from a 35-year-old man and a 75-year-old man.

The research team removed the nucleus from an egg cell and replaced it with the nucleus of an adult skin cell in a process called somatic cell nuclear transfer (SCNT). SCNT is the process that was used to create Dolly the sheep in 1996.

After shocking the cells with electricity, they began dividing until they formed a ball of a few hundred cells – a blastocyst – which has the potential to be grown into a number of different tissue types. These tissues could one day be used to treat a range of disorders including Parkinson's disease, heart disease and even spinal cord injuries.

'Therapeutic cloning has long been envisioned as a means for generating patient-specific stem cells that could be used to treat a range of age-related diseases', said Dr Robert Lanza, a co-author of the study, from Advanced Cell Technology in Massachusetts, USA.

'However, despite cloning success in animals, the derivation of stem cells from cloned human embryos has proven elusive. Only one group has ever succeeded, and their lines were generated using fetal and infant cells', he added.

Professor Shoukhrat Mitalipov, from Oregon Health and Science University, who developed the technique, said: 'The advance here is showing that (nuclear transfer) looks like it will work with people of all ages. I'm happy to hear that our experiment was verified and shown to be genuine'.

There are ethical concerns regarding the team's discovery, however. While the blastocysts created by the current research would never give rise to a human embryo, the findings raise the prospect of using a similar technique to create a cloned embryo. Dr Lanza recognises the risk of attempting to do this, remarking that it would be 'unsafe and grossly unethical' to NBC News.

Meanwhile, one of Dr Lanza's colleagues, Dong-ryul Lee, from CHA University in South Korea, has found that only relatively few human stem cell lines are needed to be able to treat numerous people without fear of immunorejection.

Lee and his colleagues discovered that 28 types of human embryonic stem cells developed in South Korea can be transplanted into up to a quarter of Koreans without being rejected by the body. This means theoretically that just 100 to 160 stem cell lines would need to be generated in order to treat the whole of the South Korean population, they suggest.

ONVO

El suelo bueno fue en los 3,9X. Ahora la tengo abandonada y hace tiempo que no leo los informes. Si tuviera pasta me la estudiaba. A mí los acuerdos con las empresas de cosméticos y la última noticia de los riñones me dicen que llevan a pensar que se dará la vuelta pronto.

PD: Aviso de que pega unos brincos análogos a una OTC.

Edito: hoy ONVO ha sacado 8K. Habría que leerlo. Y está esta noticia en SA:

3D printing stocks fall after 3D Systems' Q1 report

The numbers aren't enough to satisfy the Street, which has been selling of richly-valued 3D printing names early and often during March/April's momentum stock rout.
In addition to Stratasys (mentioned previously), ExOne (XONE -1.7%), Voxeljet (VJET -4.7%), Organavo (ONVO -5.9%), and Camtek (CAMT -1.9%) are also joining 3D Systems in selling off.

En ARNA 228K asi de golpe....

GTXI estaba esperando a que me saliera, como siempre, +15%, ainnnnnn.